Renal anemia in chronic kidney disease
Conditions
Interventions
None listed
Sponsors
Niigata University Graduate School of Medical & Dental Sciences
Foundation for Biomedical Research and Innov ation at Kobe
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are planning to start treatment with darbepoetin alfa within 8 weeks after enrollment; 2) Patients with eGFR <60 mL/min/1.73m2 at the latest examination performed within 8 weeks before enrollment; 3) Patients with a hemoglobin level <11.0 g/dL at the latest examination performed within 8 weeks before enrollment; 4) Patients aged at least 20 years or older at the time of providing informed consent; 5) Patients who voluntarily provided written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Patients who are planning to start hemodialysis or renal transplantation within 24 weeks after enrolment; 2) Patients with a history of treatment with ESA except the ones who were treated temporarily more than 12 weeks before the enrollment; 3)Patients with malignant tumor, hematological disease, or hemorrhagic lesions; 4) Patients with hypersensitivity to ESA or any ingredient thereof; 5) Pregnant, lactating or possibly pregnant women or those who wish to be pregnant during the study period; 6) Patients who are participating in other clinical study; 7) Patients who are assessed as not eligible for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deterioration of renal function, Cardiovascular disease events | — |
Countries
Japan
Contacts
Public ContactTomoko Usui
The University of Tokyo Hospital Division of Nephrology and Endocrinology
Outcome results
None listed